TEAD inhibitor IK-930: a promising targeted therapy for mesothelioma

Dean Fennell, MBBS, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, comments on the significant results from the TEAD study (NCT05228015) a Phase I, first-in-human study in which the TEAD inhibitor IK-930 brought about notable shrinkage in mesothelioma tumors in a number of participants. However, further biomarker testing of the NF2 gene, hypothesized to dispose TEAD-inhibitor sensitivity, did not neatly correlate with the clinical outcomes, encouraging further research. These findings fit into a broader picture of developing therapeutics to target specific, known mutations. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.